FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      amgnndaq

      ·

      Amgen Reports Positive Trial Results for TEPEZZA

      Amgen Inc. (NASDAQ:AMGN) has been identified as one of the most profitable value stocks currently available for investors. The company has garnered attention for its strong financial performance and growth potential in the biotechnology sector.

      On April 6, Amgen announced that it achieved positive topline results from a Phase 3 clinical trial. The trial evaluated a subcutaneous formulation of TEPEZZA, a treatment aimed at patients suffering from moderate-to-severe active thyroid eye disease. These results are expected to bolster Amgen's position in the market and enhance its product offerings.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud